TOKYO -- Fujifilm Holdings, developer of anti-flu treatment Avigan, will invest about 100 billion yen ($928 million) to ramp up production of biopharmaceuticals at its plant in Denmark, the company announced Tuesday, in response to increasing demand for medicines as therapeutic agents.
Toward that end, the Japanese company will double capacity of special cell culture tanks used for making drugs. It also plans to introduce a formulation and packaging facility to process them, thus building a system for integrated production.
